Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)
| Market Cap | $7.38B+125.8% |
| Revenue (ttm) | $945.96M+58.2% |
| Net Income | $109.57M+205.1% |
| EPS | $1.31+191.1% |
| Shares Out | 78.57M |
| PE Ratio | 65.66 |
| Forward PE | 44.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 545,145 |
| Open | $93.91 |
| Previous Close | $93.53 |
| Day's Range | $92.95 - $95.23 |
| 52-Week Range | $37.02 - $99.31 |
| Beta | 0.08 |
| Analysts | Buy |
| Price Target | $97.40(+3.73%) |
| Earnings Date | Feb 23, 2027 |
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
4 firms rating KNSA in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 23, 2027Earnings report
$KNSA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in KNSA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by KNSA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
KNSA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New KNSA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to KNSA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in KNSA
| IWMiShares Russell 2000 ETF | $111.88M |
| VTIVanguard Morningstar Total Stock Market ETF | $101.36M |
| VBVanguard Morningstar Small-Cap ETF | $89.89M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $50.31M |
| IWOiShares Russell 2000 Growth ETF | $40.49M |
| DFASDimensional - US Small Cap ETF | $29.66M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from KNSA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Analyst upgrades and growth catalysts outweigh routine insider selling and conference presentation activity.
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 25Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| HYP | Golden Eagle Dynamic Hypergrowth ETF | 2.83% |
| AFSC | abrdn Focused U.S. Small Cap Active ETF | 2.64% |
| BBP | Virtus Biotech ETF | 2.37% |
| FFTY | CapForce IBD 50 ETF | 2.32% |
| FORH | Formidable ETF | 1.39% |
| HELX | Franklin Genomic Advancements ETF | 1.21% |
| EHLS | Even Herd Long Short ETF | 1.11% |
| SMCF | Themes US Small Cap Cash Flow Champions ETF | 1.10% |
| JSML | Janus Henderson Small Cap Growth Alpha ETF | 1.02% |
| AFSM | First Trust Active Factor Small Cap ETF | 0.92% |
| ABLS | Abacus FCF Small Cap Leaders ETF | 0.87% |
| NTRL | First Trust Merger Arbitrage ETF | 0.76% |
Weight is the stock’s share of each fund’s holdings.
